Drug development, commercial strategy, device innovation, and AI in the pipeline, covered for the teams bringing therapies and technologies to market.
11 stories in Pharma & Biotech
The first publicly announced pembrolizumab biosimilar is under FDA review just as Merck accelerates subcutaneous conversion abroad, leaving oncology service lines roughly 18 months to model two very different futures.
Fresh scrutiny of industry ties among FDA adcomm members turns a once-predictable regulatory milestone into a variable that payers, P&T committees and commercial teams now have to price in.
A two-week wave of obesity, bispecific and ADC deals shows US and EU drugmakers buying their next assets from Chinese biotechs, and the effects will land on pharmacy budgets by 2028.
PhRMA's Oct. 7 lawsuit against CMS puts the Part B most-favored-nation demonstration on a court calendar, forcing hospital pharmacy and finance leaders into dual-track budgeting for 2027 and 2028.
HRSA has approved 10 manufacturers for the 340B rebate pilot, flipping covered entities from an upfront discount to a back-end rebate and turning a pricing debate into a working-capital problem.
A temporary Medicare demonstration created a 700,000-patient obesity cohort in under 90 days, concentrating 70% of new starts with one manufacturer and resetting what health systems must staff and negotiate for 2027.
A narrowing pool of mega-acquirers, new most-favored-nation pricing deals and China-sourced licensing are reshaping which drugs reach hospital formularies, and most 24-month forecasts have not caught up.
Medicare's third negotiation cycle is the first to reach physician-administered drugs, which turns a pharmacy benefit story into a provider revenue story for hospitals, infusion centers and oncology practices.
The White House's newest round of most favored nation pricing agreements covers nine midsized manufacturers, shifting exposure toward specialty and rare disease products with no easy substitute.
Pharma's headline AI discovery partnerships now run past $1B, but cash at signing is typically $30M to $50M. Health system and payer leaders should plan for the pipeline, not the press release.
Twenty-six companies now cover 89% of the branded drug market under voluntary MFN agreements, but SEC filings show three-year terms with sunset dates buyers cannot see.
